ILC: J&J's RNAi suppresses hepatitis B for 48 weeks after last dose ILC: Searching for a functional cure while battling rivals, Vir and Alnylam post hep B data peek AbbVie pens $30M Harvard University viral pact with coronavirus in the crosshairs Sponsored: Improve outcomes for TIL therapies by tackling process challenges Asking the right questions, recruiting the right patients: AI in clinical trials Athira, armed with data on 11 patients, plans $100M IPO to fund pivotal Alzheimer's trial Amazon debuts first health-focused wearable—built to track daily steps, tone of voice and emotional states After Icon, PPD and Syneos, Pfizer pens updated Parexel deal, a clean sweep of re-upped CRO deals FiercePharmaAsia—Japan COVID-19 vaccine deals; Samsung Biologics' $2B super plant; Eisai's new U.S. HQ Chutes & Ladders—Apic brings on Solid Bio vet Quiroz to chief medical role Featured Story | By Nick Paul Taylor Johnson & Johnson has presented clinical trial data linking short-term treatment with RNAi therapy JNJ-3989 to sustained reductions in markers of hepatitis B infection. The data drop comes as J&J runs 48-week phase 2b trials of the Arrowhead-partnered drug in the pursuit of a functional cure. read more |
| |
|---|
|
Top Stories By Ben Adams The battle to be the first RNAi to help cure hepatitis B is heating up as Vir and partner Alnylam release ongoing data and rivals line up with their own results at the International Liver Congress 2020. read more By Ben Adams AbbVie and Harvard have signed up to a new $30 million early-stage infectious disease pact with coronavirus and hemorrhagic fever viruses two key targets of the deal. read more Sponsored By: Cytiva The efficacy of TIL therapies depends on how the original tumor samples are collected, harvested, and processed. read more By Amirah Al Idrus From discovering compounds that could eventually become drugs to training chatbots to support patients taking those drugs, artificial intelligence can play a role anywhere along the drug development cycle. One of those points is clinical trials, where this technology can make studies easier for patients and investigators to navigate, and ultimately help biopharma companies make the best drugs they can. read more By Nick Paul Taylor Athira Pharma has filed to raise $100 million on public markets to take a treatment for Alzheimer’s and Parkinson’s diseases through phase 2 clinical trials. The IPO will fund development of an HGF/MET activator Athira thinks can treat neurological diseases by promoting a natural regenerative system. read more By Conor Hale Amazon has launched its own fitness wearable and health app, built not just to log a person’s physical activity, but to also track their emotional well-being, by scanning the tone of their voice day-to-day. read more By Ben Adams Pfizer has signed a new three-year deal with contract research organization Parexel, adding to its decade-long collab. read more By Angus Liu AstraZeneca taps Daiichi Sankyo and others to help supply its COVID-19 vaccine to Japan, as Takeda licenses Novavax's coronavirus shot for its home country. Samsung Biologics is plotting a giant $2 billion facility at its Incheon base. Eisai will relocate its U.S. headquarters. And more. read more By Kyle Blankenship Apic brings Quiroz over from Solid Bio as CMO; Kura nabs Dale as CMO; troubled Moffitt Cancer Centers brings on Hwu. read more Enrollment Showcase | Presented by: Biotility Taught by experienced professionals, Biotility’s online short courses provide the knowledge and practical skills valued by the bioscience industry. Enhance your career through coursework in one of our certificate pathways, including Document Management, Operations Management, and Quality Management. Learn more. |
| |
|---|
|
Resources Sponsored by: LexisNexis Risk Solutions Traditionally, pharma companies use a combination of prescription data & internal sales reports to look for potential buyers. Such practice provides only a LIMITED VIEW without competitor information. Sponsored by: Optum Download the whitepaper by Optum to see how novel data platforms can uncover hidden insights on medication adherence helping life sciences companies maximize product utilization. Sponsored by: Evotec Two informative webcasts will present practical and methodological approaches to preclinical drug abuse liability assessment Sponsored by: Oracle Health Sciences Patient-facing digital technologies are playing an important role in clinical trials for new drugs and medical devices, to the point where conducting virtual trials is becoming mainstream. But terms like remote trials, direct-to-patient trials, hybrid trials, decentralized trials, and more all add to the confusion of what makes a trial "virtual." Sponsored by: Oracle Health Sciences The research conducted here is to help understand and solve the top challenges in clinical operations, to remove barriers that are slowing down our ability to bring new drugs to market as quickly as possible to patients waiting in need. Sponsored by: Thermo Fisher Scientific How to select the right dosage form for your Phase I clinical supply. Sponsored by: Thermo Fisher Scientific Quality by Design (QbD) reduces risk within drug development, while bringing therapies to market quicker. Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Acorn AI by Medidata, a Dassault Systèmes company Case Study: Oncology-focused pharmaceutical company strengthens product launch by identifying hundreds of high-value physicians with Acorn AI. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Cardinal Health 3PL Services Identifying opportunities to simplify channel strategies and business processes for biopharma companies, their customers and patients. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: PRA Health Sciences Drug developers and stakeholders must find ways to collaborate, rather than compete, as the RACE Act prompts the need for more pediatric research. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Biomanufacturing Class. Live, Online. Oct 2. Register Today! October 2, 2020 | 9am - 3:30pm ET Drug Development Immersion: Live, Online Course October 21-22, 2020 | 9am - 3:30pm ET BioBasics 101: The Biology of Biotech for the Non-Scientist: Live, Online Course November 12-13, 2020 | 9am - 3:30pm ET Drug Development Boot Camp® VIRTUAL 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now | Due to COVID19 provisions – training will be conducted VIRTUALLY | Same excellent total immersion training in new medicine development will be made available to experts who want to make a difference to patients. | 